How is Tukysa different from other medications in the treatment of breast cancer?

Hi,

Welcome to icliniq.com.

I read your query and understand your concern.

Tukysa (Tucatinib) is a tyrosine kinase inhibitor of HER2 (a protein that causes cancer to grow fast). In vitro, Tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK (mitogen-activated protein kinase) and AKT (Protein kinase B), signaling and cell proliferation, and shows anti-tumor activity in HER2 expressing tumor cells. Tuksya is a smaller molecule than trastuzumab, so it can target the part of HER2 on the inside of cancer cells. In this way, TUKYSA and trastuzumab work together to completely block the HER2 activity that promotes the growth of cancer.

In a concise form, It disrupts the internal signaling pathway of the tumor cells and prevents tumor cell proliferation. Every medication has its own mechanism of action, and depending on the tumor type and synergistic mechanism of medicines, these are advised as part of treatment. Most of these medications are standard treatment for neoplasms and a standard regimen is followed almost all over the world. So I would suggest trust in the treatment advised to your mother and instill the same in her.

I hope this information will help you. Please revert in case of further queries.

Thank you.